These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25429431)

  • 1. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.
    Terlikowska KM; Witkowska AM; Zujko ME; Dobrzycka B; Terlikowski SJ
    Int J Mol Sci; 2014 Nov; 15(12):21703-22. PubMed ID: 25429431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
    He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
    Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
    Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin for chemoprevention of colon cancer.
    Johnson JJ; Mukhtar H
    Cancer Lett; 2007 Oct; 255(2):170-81. PubMed ID: 17448598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of oxaliplatin in epithelial ovarian cancer.
    Fu S; Kavanagh JJ; Hu W; Bast RC
    Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of platinum-resistant ovarian cancer.
    Trimble EL; Wright J; Christian MC
    Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
    Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
    J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies.
    Allegra A; Innao V; Russo S; Gerace D; Alonci A; Musolino C
    Cancer Invest; 2017 Jan; 35(1):1-22. PubMed ID: 27996308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Targets of Curcumin and Its Therapeutic Potential for Ovarian Cancer.
    Mohamadian M; Bahrami A; Moradi Binabaj M; Asgharzadeh F; Ferns GA
    Nutr Cancer; 2022; 74(8):2713-2730. PubMed ID: 35266849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Curcumin in chemoprevention of breast cancer].
    Terlikowska K; Witkowska A; Terlikowski S
    Postepy Hig Med Dosw (Online); 2014 Jan; 68():571-8. PubMed ID: 24864107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.
    Pchejetski D; Alfraidi A; Sacco K; Alshaker H; Muhammad A; Monzon L
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1659-71. PubMed ID: 26560874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
    Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
    Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
    Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
    Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.
    Pastò A; Pagotto A; Pilotto G; De Paoli A; De Salvo GL; Baldoni A; Nicoletto MO; Ricci F; Damia G; Bellio C; Indraccolo S; Amadori A
    Oncotarget; 2017 Jan; 8(4):6433-6445. PubMed ID: 28031535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.